A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.

NCT Number	NCT07258979
Lead Sponsor	MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions	Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment	202 participants
Start Date	2025-11-05
Primary Completion	2028-02 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2025-12-02